Clinical trial NCT06825624: ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
Official title: ARTEMIS-102: a Phase Ib Study of HS-20093 Combination Therapy to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced Metastatic Colorectal Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Metastatic Colorectal Cancer (CRC)
Keywords: Metastatic Colorectal Cancer (mCRC)
B7-H3
antibody-drug conjugate (ADC)
HS-20093
Lead sponsor: Hansoh BioMedical R&D Company
Sponsor class: INDUSTRY
First posted: 2025-02-13
Enrollment: 560
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and efficacy of HS-20093 in combination with other anti-cancer agents in patients with advanced metastatic colorectal cancer.

Detailed description: This is a phase 1b, open-label, multi-center, dose-escalation and expansion, phase 1b study in Chinses subjects with advanced metastatic colorectal cancer. This study is in design allowing assessment of safety, tolerability, pharmacokinetics and efficacy of HS-20093 in combination with other anti-cancer agents.

A total of 5 combination-treatments will be carried out in 5 cohorts. The target population of dose escalation part is patients have progressed on or intolerant to available standard therapies, and the dose expansion part will enroll patients who have not received treatment for advanced metastatic colorectal cancer.

All patients will be carefully followed for adverse events during the study treatment and for 90 days after the last dose of study drug. Subjects will be permitted to continue therapy with assessments for progression if the product is well tolerated and sustained clinical benefit exists.

Eligibility criteria: Inclusion Criteria:

* At least age of 18 years at screening.
* Histologically or cytologically confirmed, locally advanced or metastatic colorectal cancer.

  1. Dose escalation part will enroll advanced metastatic colorectal cancer patients who have progressed on or intolerant to standard therapies.
  2. Dose expansion part will enroll advanced metastatic colorectal cancer patients who have not received prior treatment for advanced/metastatic colorectal cancer.
* At least one measurable lesion according to RECIST 1.1.
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0\~1.
* Life expectancy \>= 12 weeks.
* Men or women should be using adequate contraceptive measures throughout the study.
* Females subjects must not be pregnant at screening or have evidence of non-childbearing potential.
* Signed and dated Informed Consent Form.

Exclusion Criteria:

* Treatment with any of the following:

  1. Previous or current treatment with B7-H3 targeted therapy or ADCs with topoisomerase I inhibitors as the payload
  2. Any cytotoxic chemotherapy, investigational agents and small molecule targeted therapy within 14 days prior to the first scheduled dose of HS-20093
  3. Prior treatment with macromolecule anti-tumor therapy or other anticancer drugs within 28 days prior to the first scheduled dose of HS-20093
  4. Radiotherapy with a limited field of radiation for palliation within 2 weeks, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first scheduled dose of HS-20093
  5. Pleural or peritoneal effusion requiring clinical intervention. Pericardial effusion
  6. Major surgery within 4 weeks of the first dose of HS-20093
  7. Spinal cord compression or brain metastases.
  8. Treatment with drugs that are predominantly CYP3A4 strong inhibitors or inducers or sensitive substrates of CYP3A4 with a narrow therapeutic range within 7 days of the first dose of study drug; or requiring treatment with these drugs during the study.
  9. Currently receiving drugs known to prolong QT interval or may cause torsade de pointe; or requiring treatment with these drugs during the study.
* Any unresolved toxicities from prior therapy greater than Grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE) 5.0 with the exception of stable hypothyroidism treated with hormone replacement therapy, alopecia or neurotoxicity.
* History of other primary malignancies.
* Inadequate bone marrow reserve or organ dysfunction
* Evidence of cardiovascular risk.
* Severe, uncontrolled or active cardiovascular diseases.
* Diabetes ketoacidosis or hyperglycemia hypertonic occurring within 6 months before the first dose of the study drug.
* Severe or poorly controlled hypertension.
* Bleeding symptoms with apparent clinical significance or obvious bleeding tendency within 1 months prior to the first dose of HS-20093
* Serious arteriovenous thrombosis events occurred within 3 months before the first dose.
* Severe infections occurred within 4 weeks before the first dose.
* Patients who have received continuous steroid treatment for more than 30 days within 30 days before the first dose, or need long-term (≥ 30 days) steroid treatment, or who have other acquired and congenital immunodeficiency diseases, or have a history of organ transplantation
* The presence of active infectious diseases has been known before the first dose such as hepatitis B, hepatitis C, tuberculosis, syphilis, or human immunodeficiency virus HIV infection, etc.
* Hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh Grade B or more severe cirrhosis.
* Other moderate or severe lung diseases that may interfere with the detection or treatment of drug-related pulmonary toxicity or may seriously affect respiratory function.
* Previous history of serious neurological or mental disorders, including epilepsy, dementia or severe depression and any other status that may interfere in assessment.
* Women who are breastfeeding or pregnant or planned to be pregnant during the study period.

  18. Vaccination or hypersensitivity of any level within 4 weeks prior to the first dose of HS-20093
* History of severe hypersensitivity reaction, severe infusion reaction or allergy to recombinant human or mouse derived proteins.
* Hypersensitivity to any ingredient of HS-20093.
* Unlikely to comply with study procedures, restrictions, and requirements in the opinion of the investigator
* Any disease or condition that, in the opinion of the investigator, would compromise subject safety or interfere with study assessments

Primary outcomes:
measure: Maximum tolerated dose (MTD) for combination-treatments
timeFrame: Up to day 21 (arm 1/3/4) or 28 (arm 2/5) from the first dose
Secondary outcomes:
measure: Incidence and severity of adverse events (AEs)
timeFrame: From the first dose through 90 days post end of treatment
measure: Objective response rate (ORR) determined by investigators
timeFrame: From the first dose up to PD or withdrawal from study, whichever came first, assessed up to 24 months
measure: Disease control rate (DCR) determined by investigators
timeFrame: From the first dose up to PD or withdrawal from study, whichever came first, assessed up to 24 months
measure: Duration of response (DoR) determined by investigators
timeFrame: From the first dose up to PD or death, whichever came first, assessed up to 24 months
measure: Progression-free survival (PFS) determined by investigators according to RECIST 1.1
timeFrame: From the first dose up to PD or death, whichever came first, assessed up to 24 months
measure: Overall survival (OS)
timeFrame: From the first dose up to death, whichever came first, assessed up to 24 months
measure: Observed maximum plasma concentration (Cmax) of HS-20093
timeFrame: From pre-dose to study completion, assessed up to 24 months
measure: Time to reach maximum plasma concentration (Tmax) of HS-20093
timeFrame: From pre-dose to study completion, assessed up to 24 months
measure: Terminal half-life (T1/2) of HS-20093 following the first dose
timeFrame: From pre-dose to study completion, assessed up to 24 months
measure: Area under plasma concentration versus time curve from zero to last sampling time (AUC0-t) following the first dose of HS-20093
timeFrame: From pre-dose to study completion, assessed up to 24 months
measure: Percentage of participants with antibodies to HS-20093 in serum
timeFrame: From pre-dose to study completion, assessed up to 24 months
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: The Second Affiliated Hospital Zhejiang University
state: Zhejiang
Study officials:
References: